Cargando…
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotei...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253482/ https://www.ncbi.nlm.nih.gov/pubmed/32461612 http://dx.doi.org/10.1038/s41467-020-16567-0 |
_version_ | 1783539341796048896 |
---|---|
author | Watanabe, Yasunori Berndsen, Zachary T. Raghwani, Jayna Seabright, Gemma E. Allen, Joel D. Pybus, Oliver G. McLellan, Jason S. Wilson, Ian A. Bowden, Thomas A. Ward, Andrew B. Crispin, Max |
author_facet | Watanabe, Yasunori Berndsen, Zachary T. Raghwani, Jayna Seabright, Gemma E. Allen, Joel D. Pybus, Oliver G. McLellan, Jason S. Wilson, Ian A. Bowden, Thomas A. Ward, Andrew B. Crispin, Max |
author_sort | Watanabe, Yasunori |
collection | PubMed |
description | Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. Coronavirus S proteins are extensively glycosylated, encoding around 66–87 N-linked glycosylation sites per trimeric spike. Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs. We provide a comparison of the global glycan density of coronavirus spikes with other viral proteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in shielding immunogenic epitopes. Overall, our data reveal how organisation of glycosylation across class I viral fusion proteins influence not only individual glycan compositions but also the immunological pressure across the protein surface. |
format | Online Article Text |
id | pubmed-7253482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-72534822020-06-05 Vulnerabilities in coronavirus glycan shields despite extensive glycosylation Watanabe, Yasunori Berndsen, Zachary T. Raghwani, Jayna Seabright, Gemma E. Allen, Joel D. Pybus, Oliver G. McLellan, Jason S. Wilson, Ian A. Bowden, Thomas A. Ward, Andrew B. Crispin, Max Nat Commun Article Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. Coronavirus S proteins are extensively glycosylated, encoding around 66–87 N-linked glycosylation sites per trimeric spike. Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs. We provide a comparison of the global glycan density of coronavirus spikes with other viral proteins including HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin, where glycosylation plays a known role in shielding immunogenic epitopes. Overall, our data reveal how organisation of glycosylation across class I viral fusion proteins influence not only individual glycan compositions but also the immunological pressure across the protein surface. Nature Publishing Group UK 2020-05-27 /pmc/articles/PMC7253482/ /pubmed/32461612 http://dx.doi.org/10.1038/s41467-020-16567-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Watanabe, Yasunori Berndsen, Zachary T. Raghwani, Jayna Seabright, Gemma E. Allen, Joel D. Pybus, Oliver G. McLellan, Jason S. Wilson, Ian A. Bowden, Thomas A. Ward, Andrew B. Crispin, Max Vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
title | Vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
title_full | Vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
title_fullStr | Vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
title_full_unstemmed | Vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
title_short | Vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
title_sort | vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253482/ https://www.ncbi.nlm.nih.gov/pubmed/32461612 http://dx.doi.org/10.1038/s41467-020-16567-0 |
work_keys_str_mv | AT watanabeyasunori vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT berndsenzacharyt vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT raghwanijayna vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT seabrightgemmae vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT allenjoeld vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT pybusoliverg vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT mclellanjasons vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT wilsoniana vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT bowdenthomasa vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT wardandrewb vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation AT crispinmax vulnerabilitiesincoronavirusglycanshieldsdespiteextensiveglycosylation |